The Guardian: Africa steps up fight against HIV with trial of new combination vaccines
“The first trial in Africa to test two new vaccines to protect against HIV got under way in Uganda this week, raising hopes of an end to the epidemic that affects millions of people across the continent. The African-led PrEPVacc study will test two experimental combination vaccines to see if they can provide any protection against HIV in people most at risk of infection. At the same time, a new form of daily oral pre-exposure prophylaxis (PrEP) will be offered to participants, which scientists say will give the vaccines the best possible chance of working…” (Okiror, 12/18).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.